Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients

Clinica Chimica Acta

Volumn 411, Issue 17-18, 2010, Pages 1319-1324

  Pinzani, Pamela ^a   Salvianti, Francesca ^a   Cascella, Roberta ^a   Massi, Daniela ^a   De Giorgi, Vincenzo ^a   Pazzagli, Mario ^a   Orlando, Claudio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Allele specific real time PCR; BRAFV600E mutation; Cell free DNA; Melanoma; Molecular marker; Noninvasive diagnosis

Indexed keywords

B RAF KINASE; LOCKED NUCLEIC ACID; BRAF PROTEIN, HUMAN; DNA; PRIMER DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; NON INVASIVE PROCEDURE; NUCLEIC ACID PROBE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ALLELE; BLOOD; CELL FREE SYSTEM; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROCEDURES; SKIN TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BASE SEQUENCE; CELL-FREE SYSTEM; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 77954145469     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.05.024     Document Type: Article

References (28)

1. Thomas N.E. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006, 16:97-103.
2. Yancovitz M., Yoon J., Mikhail M., et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 2007, 9:178-183.
3. Kuphal S., Bosserhoff A. Recent progress in understanding the pathology of malignant melanoma. J Pathol 2009, 2194:400-409.
4. Peyssonnaux C., Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93:53-62.
5. Marais R., Light Y., Paterson H.F., Mason C.S., Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997, 272:4378-4383.
6. Smalley K.S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer 2003, 1045:527-532.
7. Pratilas C.A., Solit D.B. Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials 2007, 2:121-134.
8. Gruber F., Kastelan M., Brajac I., et al. Molecular and genetic mechanisms in melanoma. Coll Antropol 2008, 32(Suppl2):147-152.
9. Shinozaki M., O'Day S.J., Kitago M., et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 2007, 13:2068-2074.
10. Chang D.Z., Panageas K.S., Osman I., Polsky D., Busam K., Chapman P.B. Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2004, 2:46.
11. Chudnovsky Y., Khavari P.A., Adams A.E. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005, 115:813-824.
12. Shinozaki M., Fujimoto A., Morton D.L., Hoon D.S. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004, 10:1753-1757.
13. Pollock P.M., Harper U.L., Hansen K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33:19-20.
14. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
15. Smalley K.S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer 2003, 104:527-532.
16. Satyamoorthy K., Li G., Gerrero M.R., et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63:756-759.
17. Nathanson K.L. Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem Pharmacol 2010, 10.1016/j.bcp.2010.04.017.
18. V600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 2007, 120:2439-2444.
19. Goessl C. Diagnostic potential of circulating nucleic acids for oncology. Expert Rev Mol Diagn 2003, 3:431-442.
20. Lehmann U., Glöckner S., Kleeberger W., von Wasielewski H.F., Kreipe Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000, 156:1855-1864.
21. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
22. Simi L., Pratesi N., Vignoli M., et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130:247-253.
23. Oldenburg R.P., Liu M.S., Kolodney M.S. Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J Invest Dermatol 2008, 128:398-402.
24. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007, 1775:181-232.
25. van der Vaart M., Pretorius P.J. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?. Clin Biochem 2010, 43:26-36.
26. Sorenson G.D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000, 6:2129-2137.
27. Vdovichenko K.K., Markova S.I., Belokhvostov A.S. Mutant form of BRAF gene in blood plasma of cancer patients. Ann N Y Acad Sci 2004, 1022:228-231.
28. Lilleberg S.L., Durocher J., Sanders C., Walters K., Culver K. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann N Y Acad Sci 2004, 1022:250-256.